Findlay Park Partners LLP Invests $214.20 Million in West Pharmaceutical Services, Inc. $WST

Findlay Park Partners LLP acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) in the second quarter, HoldingsChannel.com reports. The fund acquired 596,646 shares of the medical instruments supplier’s stock, valued at approximately $214,196,000. West Pharmaceutical Services accounts for 2.9% of Findlay Park Partners LLP’s portfolio, making the stock its 10th biggest position.

A number of other institutional investors also recently added to or reduced their stakes in WST. Elyxium Wealth LLC purchased a new position in West Pharmaceutical Services in the fourth quarter valued at about $25,000. CYBER HORNET ETFs LLC acquired a new position in shares of West Pharmaceutical Services in the second quarter valued at approximately $25,000. Cornerstone Planning Group LLC boosted its holdings in shares of West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 50 shares during the last quarter. Bayban purchased a new position in West Pharmaceutical Services during the fourth quarter worth about $27,000. Finally, Avalon Trust Co purchased a new stake in West Pharmaceutical Services in the second quarter valued at approximately $28,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Wall Street Analyst Weigh In

WST has been the topic of several research reports. KeyCorp raised their price target on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. Morgan Stanley increased their target price on West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Citigroup lifted their price target on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Evercore reiterated an “outperform” rating and set a $425.00 price objective on shares of West Pharmaceutical Services in a research note on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $368.08.

West Pharmaceutical Services Price Performance

Shares of WST opened at $352.94 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. West Pharmaceutical Services, Inc. has a 12 month low of $223.83 and a 12 month high of $386.00. The stock has a fifty day moving average price of $348.61 and a 200 day moving average price of $299.75. The company has a market cap of $24.84 billion, a P/E ratio of 45.19, a PEG ratio of 2.47 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. The firm had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. West Pharmaceutical Services’s revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, research analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is currently 11.27%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.